

EMBARGOED FOR RELEASE until November 13 – 5:00 PM (ET)

Contacts: Tracy Hampton • (312) 339-9067 • thampton@nasw.org
Bob Henkel • (202) 557-8360 • bhenkel@asn-online.org

GUIDELINES INDICATE THAT NEARLY ALL PATIENTS WITH CHRONIC KIDNEY DISEASE SHOULD TAKE STATINS

Two separate cholesterol management guidelines are in agreement

Highlights

- A comparison of two different cholesterol management guidelines indicates that the vast majority of patients with chronic kidney disease are recommended to receive statins.
- 50% of people with chronic kidney disease who are recommended to receive statins are not taking them.

More than 20 million US adults have chronic kidney disease.

Washington, DC (November 13, 2014) — Almost all people with pre-dialysis kidney disease should receive statins by current guidelines, reports a study appearing in an upcoming issue of the *Journal of the American Society of Nephrology* (JASN).

Because individuals with chronic kidney disease (CKD) have an increased risk for developing heart disease, preventive measures such as maintaining normal cholesterol levels are important. In 2013, two cholesterol management guidelines were published: one by the American College of Cardiology/American Heart Association (ACC/AHA) and another by the Kidney Disease Improving Global Outcomes Lipid Work Group (KDIGO). The ACC/AHA guideline recommends statin treatment for individuals with a high heart disease and stroke risk based on having a history of heart problems, diabetes, or very high cholesterol, or for those with an estimated 10-year risk $\geq 7.5\%$ using a formula called the “Pooled Cohorts risk equations”. In contrast, the KDIGO guideline recommends statin therapy for all individuals 50 to 79 years of age with CKD.

Although individuals with CKD are in general more likely to develop heart disease than individuals without CKD, some may be considered at low risk by the ACC/AHA cholesterol treatment guideline. So which guideline should these patients follow?

To investigate, Lisandro Colantonio, MD, MSc, Paul Muntner, PhD (University of Alabama at Birmingham School of Public Health) and their colleagues compared the two

treatment recommendations using data from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study, a large study of more than 30,000 US adults.

Among the major findings:

- 92% of people with CKD are recommended to receive statin treatment by the ACC/AHA guideline vs. 100% according the KDIGO guideline.
- 50% of people with CKD who are recommended to receive statins are not taking them.
- The new Pooled Cohort risk equations are accurate among people with CKD, indicating that physicians have a valid tool available to estimate heart disease risk for their patients with CKD.

“These results indicate that either guideline can be used to inform the decision to initiate statin therapy for people with CKD who are 50 to 79 years of age,” said Dr. Colantonio. “They also show that there is an unmet treatment need and a missed opportunity for lowering heart disease risk among patients with CKD.” Dr. Colantonio notes that “The accuracy of the pooled cohort risk equations in people with CKD is important given their high risk for heart disease and stroke. Physicians can use this tool in guiding therapy for patients with CKD.”

Study co-authors include Usman Baber, MD, Maciej Banach, MD, PhD, Rikki Tanner, MPH, David Warnock, MD, Orlando Gutiérrez, MD, Monika Safford, MD, Christoph Wanner, MD, and George Howard, DrPH.

Disclosures: Drs. David Warnock, Monika Safford and Paul Muntner have received grant support from Amgen Inc. Dr. Lisandro Colantonio was funded with a Fulbright Scholarship to complete the PhD program in Epidemiology from the University of Alabama at Birmingham.

The article, entitled “Contrasting Cholesterol Management Guidelines for Adults with CKD,” will appear online at <http://jasn.asnjournals.org/> on November 13, 2014.

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

The American Society of Nephrology®, ASN®, Kidney Week®, CJASN®, JASN®, NephSAP®, and ASN Kidney News® are registered trademarks of ASN

Founded in 1966, and with more than 15,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.

#

Tweet: Guidelines indicate that nearly all patients with chronic kidney disease should take statins.
<http://www.bit.ly/ASN-XXXX>

Facebook: Almost all people with pre-dialysis kidney disease should receive statins by current guidelines, reports a study in the *Journal of the American Society of Nephrology*.

Nicole Wyatt | Media Specialist

Office of Public Relations and Marketing

UAB | The University of Alabama at Birmingham

O: 205.934.8938 | M: 205.603.7027 | nwyatt@uab.edu